DF
LCTX icon

Define Financial’s Lineage Cell Therapeutics LCTX Stock Holding History

Define Financial’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-20,000
Closed -$31.6K – 48
2026
Q1 		$31.6K Hold
20,000
– – 0.02% 41
2025
Q4 		$33.4K Buy
+20,000
New +$34.6K 0.02% 43

Other funds holding LCTX

DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
TCOT
Trust Company of Toledo Holland, Ohio $1.2B AUM 33.38% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
BWCS
Beirne Wealth Consulting Services Shelton, Connecticut $503M AUM 27.98% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return
PI
PFG Investments Woodbury, New York $2.58B AUM 36.93% 1-Year Est. Return
CD
Chapin Davis Baltimore, Maryland $569M AUM 145.59% 1-Year Est. Return
AFG
Allegheny Financial Group Pittsburgh, Pennsylvania $942M AUM 20.23% 1-Year Est. Return
FCMT
Founders Capital Management (Texas) Houston, Texas $231M AUM 61.68% 1-Year Est. Return

Define Financial's LCTX Position: Q2 2026 in Review

Define Financial sold out of Lineage Cell Therapeutics (LCTX) in Q2 2026, closing a stake of 20,000 shares — an estimated $31.6K sold.

Define Financial first reported a position in LCTX in Q4 2025 and held it in 2 quarters. The position peaked at $33.4K in Q4 2025. 19 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Define Financial reported no remaining Lineage Cell Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Define Financial sold 20,000 Lineage Cell Therapeutics shares in Q2 2026, an estimated $31.6K.
  • Define Financial first reported a position in Lineage Cell Therapeutics in Q4 2025 and held it in 2 quarters.
  • Define Financial's Lineage Cell Therapeutics position peaked at $33.4K in Q4 2025.
  • 19 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Define Financial's 13F filing for Q2 2026, filed 14 Jul 2026.